Cosmo and Takeda Renew Strategic Manufacturing Agreement for Global Supply of Oral Treatment for Ulcerative Colitis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 08 2025
0mins
Should l Buy ?
Source: Yahoo Finance
Agreement Renewal: Cosmo Pharmaceuticals has renewed its multi-year manufacturing and supply agreement with Takeda for the production of Mesalazine MMX 1200 mg, reinforcing their collaboration and commitment to high-quality pharmaceutical solutions.
Company Overview: Cosmo is a life sciences company specializing in MedTech AI and gastrointestinal diseases, with a focus on innovation and sustainability, operating advanced manufacturing facilities approved by global regulatory authorities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
